Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

IGF-1 LR3 Side Effects: Study Comparison

Hypoglycemia 25–35 mg/dL glucose drop in rats (Endocrinology 2004) 0.5–1.5 mg/kg daily Resolves 24–48h post-dose Anecdotal reports only. No clinical trials Insulin receptor desensitisation 40–50% receptor downregulation in hepatocytes after 6 weeks (JBC 2011)

This comparison does not assign a generated winner or score.

  • Hypoglycemia
  • 25–35 mg/dL glucose drop in rats (Endocrinology 2004)
  • 0.5–1.5 mg/kg daily
  • Resolves 24–48h post-dose
  • Anecdotal reports only. No clinical trials
  • Insulin receptor desensitisation
  • 40–50% receptor downregulation in hepatocytes after 6 weeks (JBC 2011)
  • 1 mg/kg daily for ≥6 weeks
  • Partial recovery after 4-week washout
  • Not measured in humans
  • Cardiac hypertrophy
  • 18% increase in left ventricular mass in rats (GH&IGF 2009)
  • 1 mg/kg daily for 8 weeks
  • No recovery observed in 4-week follow-up
  • Hepatomegaly
  • 22% increase in liver weight relative to body weight (GH&IGF 2009)
  • Persistent after 4-week washout
  • Joint pain / acromegaly-like effects
  • Not modeled in animal studies. Cartilage overgrowth not measured
  • N/A
  • Unknown
  • Frequent anecdotal reports in user communities
More references

Related material